Abbott Laboratories (NYSE:ABT) will be announcing its earnings results before the market opens on Thursday, July 20th. Analysts expect the company to announce earnings of $0.60 per share for the quarter. Abbott Laboratories has set its FY17 guidance at $2.40-2.50 EPS.
Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, April 19th. The healthcare product maker reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.05. The company had revenue of $6.34 billion for the quarter, compared to analysts’ expectations of $6.16 billion. Abbott Laboratories had a net margin of 6.74% and a return on equity of 14.91%. Abbott Laboratories’s revenue was up 29.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.41 EPS. On average, analysts expect Abbott Laboratories to post $2.47 EPS for the current fiscal year and $2.76 EPS for the next fiscal year.
Shares of Abbott Laboratories (NYSE ABT) opened at 48.76 on Tuesday. The company has a 50 day moving average of $46.26 and a 200-day moving average of $43.65. The company has a market cap of $84.61 billion, a PE ratio of 50.74 and a beta of 1.06. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $49.59.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be given a dividend of $0.265 per share. The ex-dividend date of this dividend is Wednesday, July 12th. This represents a $1.06 dividend on an annualized basis and a yield of 2.17%. Abbott Laboratories’s dividend payout ratio (DPR) is 110.42%.
TRADEMARK VIOLATION NOTICE: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.com-unik.info/2017/07/18/abbott-laboratories-abt-set-to-announce-quarterly-earnings-on-thursday.html.
A number of brokerages recently weighed in on ABT. UBS AG restated a “neutral” rating and set a $41.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, April 18th. BMO Capital Markets restated a “hold” rating and set a $48.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, July 11th. Guggenheim began coverage on shares of Abbott Laboratories in a research report on Thursday, June 29th. They set a “buy” rating and a $58.00 price objective on the stock. Cowen and Company restated an “outperform” rating and set a $55.00 price objective (up previously from $48.00) on shares of Abbott Laboratories in a research report on Friday. Finally, Morgan Stanley restated an “equal weight” rating on shares of Abbott Laboratories in a research report on Monday, July 10th. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $51.33.
In related news, insider Roger Bird sold 5,600 shares of the firm’s stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $43.82, for a total transaction of $245,392.00. Following the completion of the transaction, the insider now directly owns 51,313 shares of the company’s stock, valued at $2,248,535.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jared Watkin sold 552 shares of the firm’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $47.97, for a total transaction of $26,479.44. Following the transaction, the insider now directly owns 47,090 shares of the company’s stock, valued at $2,258,907.30. The disclosure for this sale can be found here. Insiders have sold a total of 206,902 shares of company stock worth $9,497,761 over the last 90 days. Insiders own 0.76% of the company’s stock.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
What are top analysts saying about Abbott Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abbott Laboratories and related companies.